Dementia and Alzheimer Disease

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 2, 2021.

ICER’s health-benefit price benchmark range for aducanumab is $3000 to $8400 per year for patients with early Alzheimer disease, substantially lower than the current $56,000 annual price listing.

Both high PiB and low entorhinal fluorodeoxyglucose as inclusion criteria reduced 3-fold the number of participants needed in a hypothetical trial compared to using only high PiB.

Patients who received high-dose blarcamesine experienced a 14.51-point MDS-UPDRS total score improvement compared to placebo in a phase 2 study of the Anavex Life Sciences agent.

Clive Ballard, MD, discussed up-and-coming technologies for remote risk assessment, among other data presented at this year’s AAIC meeting.

Hermona Soreq, PhD, discusses the complexities of aducanumab’s FDA approval, her initial reaction to the news, and whether it might be greenlit by other country’s regulators.

The executive director of the LEAD Coalition calls for greater collaboration and support from government and the healthcare community in order to boost health equity.

Here's what is coming soon to NeurologyLive.

We kindly ask you to share 5 minutes of your time with us in order to help us better understand how you use social media and how we can better serve you across different platforms.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 25, 2021.

Eli Lilly plans on submitting a biologics license application for donanemab under the accelerated approval pathway based on data from the phase 2 TRAILBLAZER-ALZ study.

The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences provided thoughts on the comfortability of prescribing aducanumab knowing its safety profile.

The decision to grant breakthrough therapy designation was based off the proof-of-concept phase 2b study which explored the impact of lecanemab, formerly BAN2401, on reducing brain amyloid beta and clinical decline.

The professor of Molecular Neuroscience at the Edmond and Lily Safra Center for Brain Sciences discussed her and her colleague’s initial response to the FDA’s approval of aducanumab.

The CEO of CENTOGENE discussed the recently announced EFRONT study in FTD and the role that rare disease genetic data collection can play in providing insights into disease intervention and treatment.

Here's what is coming soon to NeurologyLive.

Luca Giliberto, MD, PhD, and Cristina d’Abramo, PhD, share more than a marriage: After years of research, their combined efforts to develop a passive immunotherapy for Alzheimer disease have earned them a $2 million grant from the National Institutes of Health.

Neurology News Network for the week ending June 19, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending June 18, 2021.

While the relationship between sleep and cognition needs to be further studied, sleep-based interventions may be a future approach to help prevent cognitive decline.

Biogen’s investigational antibody against the N-terminus of tau failed to meet any of the efficacy or exploratory end points in individuals with mild cognitive impairment or mild Alzheimer disease.

Primary and secondary end points of the trial will assess safety and both cognitive and functional efficacy, measured through ADAS-Cog, ADCS-ADL, and CDR-SB.

Drs Richard S. Isaacson and Marc E. Agronin look to the future of treating Alzheimer disease with the emphasis on early diagnosis.

The use of blood-based biomarkers for diagnosis of Alzheimer disease in the context of the comprehensive diagnosis. 

Impact of the approval of aducanumab on the treatment landscape and other drugs in development for the treatment of Alzheimer disease.

The challenges of identifying the appropriate patient, earlier in the disease course, for treatment with aducanumab for Alzheimer disease.

The importance of the ongoing EMBARK phase III clinical trial and the collection of real-world data on the use of aducanumab is discussed.

Expert neurologists, Richard S. Isaacson, MD, and Marc E. Agronin, MD, describe the journey to the FDA approval of aducanumab for the treatment of Alzheimer disease and what this means for clinicians.

Here's what is coming soon to NeurologyLive.